According to Stock Target Advisor Ratings, Editas Medicine, Inc. (EDIT:NSD) has an average “Hold” rating from the nineteen research firms covering the company. The average price target for the EDIT stock is $13.88 over the next 12 months, according to analysts who have issued a report on the stock within the last year.
EDIT Stock-Analyst Ratings:
Several equities analysts have recently issued reports on Editas Medicine. Wells Fargo & Company reduced the price objective for the shares from $36.00 to $30.00 in a report on Thursday, February 23rd.
Credit Suisse Group increased their price objective for the shares from $13.00 to $15.00 and gave the company a “Neutral” rating in a report on Thursday, February 23rd.
Citigroup issued a “Neutral” rating and a $11.00 price objective on the stock in a report on Tuesday, December 13th. Finally, Morgan Stanley reduced their price objective for the shares from $8.00 to $7.00 and gave the EDIT stock an “Underweight” rating in a report on Tuesday, January 24th.
EDIT Stock Analysis:
Editas Medicine’s stock opened at $6.71 on Wednesday, with a 50-day moving average price of $8.70 and a 200-day moving average price of $9.86. The company has a market capitalization of $462.79 million, a PE ratio of -2.09, and a beta of 1.86. The company’s 52-week low is $6.45, and the high is $19.97.
Quarterly Earnings Review:
In the company’s last quarterly earnings results posted on Wednesday, February 22nd, Editas Medicine reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.04). Editas Medicine had a negative net margin of 1,118.32% and a negative return on equity of 50.28%.
The company had revenue of $6.54 million for the quarter, compared to the consensus estimate of $3.76 million. During the same period in the prior year, the firm posted ($0.61) EPS. The business’s revenue was down 47.6% on a year-over-year basis. On average, analysts forecast that Editas Medicine will post -$3 earnings per share for the current year.
Insider Transactions:
Recently, company CFO Michelle Robertson sold 4,287 shares of Editas Medicine stock at an average price of $9.67, for a total transaction of $41,455.29. Following the completion of the sale, Robertson directly owns 76,243 shares in the company, valued at $737,269.81.
Additionally, EVP Mark S. Shearman sold 2,790 shares of Editas Medicine stock at an average price of $9.67, for a total transaction of $26,979.30. Following the sale, Shearman directly owns 65,559 shares of the company’s stock, valued at $633,955.53.
Insiders sold a total of 7,708 shares of the EDIT stock in the last 90 days, with insiders owning 1.30% of the company’s stock.
Hedge Funds & Institutional Holdings:
Institutional investors and hedge funds have recently added or reduced their stakes in the business. Covestor Ltd increased its position in Editas Medicine by 9,693.3% in the first quarter. Quantbot Technologies LP acquired a new position in shares of Editas Medicine in the first quarter.
Company Profile:
Editas Medicine, Inc., a clinical-stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology.
The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
